Buscar
Q32 Bio Inc
QTTBAñadir a la lista de seguimiento
15.140USD
-0.010-0.07%
Cierre 07-27 16:00（ET）Cotizaciones retrasadas 15 min
186.29MCap. mercado
5.43P/E TTM
Más Datos de Q32 Bio Inc Compañía
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
Información de Q32 Bio Inc
Símbolo de cotizaciónQTTB
Nombre de la empresaQ32 Bio Inc
Fecha de salida a bolsaMar 28, 2018
Director ejecutivoMorrison (Jodie Pope)
Número de empleados42
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 28
Dirección830 Winter Street
CiudadWALTHAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02451
Teléfono17819990232
Sitio Webhttps://www.q32bio.com/
Símbolo de cotizaciónQTTB
Fecha de salida a bolsaMar 28, 2018
Director ejecutivoMorrison (Jodie Pope)
Ejecutivos de Q32 Bio Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
73.10K
-25.65%
Dr. Isaac Manke
Dr. Isaac Manke
Independent Director
Independent Director
53.52K
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
23.10K
-285.66%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Dr. Adrien Sipos, M.D., Ph.D.
Dr. Adrien Sipos, M.D., Ph.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Dr. Arthur O. Tzianabos, Ph.D.
Dr. Arthur O. Tzianabos, Ph.D.
Director
Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Mr. Diyong Xu
Mr. Diyong Xu
Independent Director
Independent Director
--
--
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
73.10K
-25.65%
Dr. Isaac Manke
Dr. Isaac Manke
Independent Director
Independent Director
53.52K
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
23.10K
-285.66%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Dr. Adrien Sipos, M.D., Ph.D.
Dr. Adrien Sipos, M.D., Ph.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Dr. Arthur O. Tzianabos, Ph.D.
Dr. Arthur O. Tzianabos, Ph.D.
Director
Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Q32 Bio Inc?
Los cinco principales accionistas de Q32 Bio Inc son: Dr. Shelia M. Violette, Ph.D.
¿Cuántas instituciones poseen acciones de Q32 Bio Inc (QTTB)?
A fecha de 2026Q1, 189 instituciones poseen acciones de Q32 Bio Inc, con un valor de mercado combinado de aproximadamente 9.99M, lo que representa el 65.09% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2048479.00.